X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX) library drug discovery engine to the generation of novel small molecule therapeutics, recently announced the signing of a broad strategic drug discovery collaboration with Bristol-Myers Squibb
AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-01, for the treatment of Fabry disease
LONDON, Silence Therapeutics, PLC (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announcesthe addition of a new siRNA (short interfering RNA) asset to its pre-clinical pipeline for the potential treatment of cardiovascular disease
Chugai Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD)
UroGen Pharma Ltd., a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, recently announced that it has initiated the rolling submission with the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) for UGN-101 (mitomycin gel) for instillation as a treatment for patients with low-grade upper tract urothelial cancer (LG UTUC)
C4X Discovery Holdings plc, a pioneering drug discovery company, recently announces that it has entered into an exclusive target discovery partnership with Horizon Discovery Group plc (“Horizon”, AIM: HZD), a global leader in the application of gene editing and gene modulation technologies
FibroGen, Inc. (NASDAQ:FGEN) today announced that FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorization from the National Medical Products Administration (NMPA) for roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of patients with anemia caused by chronic kidney disease (CKD) in patients who are dialysis-dependent (DD)
With 97 percent of all drug discovery programs failing, the development of a single new therapeutic involves an average cost of $2.6 billion
Dr. Spyro Mousses, CEO of Systems Oncology, LLC, announced Systems Oncology’s diversified pipeline of innovative oncology programs discovered with the help of Artificial Intelligence at the AIMed North America Conference in Dana Point, California
A new study published ahead-of-print by SLAS Discoverydescribes an evaluation of microplate-based high-throughput cellular thermal shift assay (CETSA HT) performed at AstraZeneca to assess its suitability and reliability for application to early drug discovery campaigns
|
|
|
|
|
|
|
|
|